The accurate clinical interpretation of human sequence variation is foundational to 19 personalized medicine. This remains a pressing challenge, however, as genome 20 sequencing becomes routine and new functionally undefined variants rapidly 21 accumulate. Here, we describe a platform for the rapid generation, characterization and 22 this study has focused on modelling NPC, the outlined approach could be translated 37 widely and applied to a variety of genetic disorders or understanding the pathogenicity 38 of somatic mutations in cancer. 39 40 Reference Sequence: NG_012795.1 NPC1: g.54927_54954del], resulting in a frame-132
interpretation of genomic variants in haploid cells focusing on Niemann-Pick disease 23 type C (NPC) as an example. NPC is a fatal neurodegenerative disorder characterized 24 by a lysosomal accumulation of unesterified cholesterol and glycolipids. In 95% of 25 cases, NPC is caused by mutations in the NPC1 gene, where over 200 unique disease-26 causing variants have been reported to date. Furthermore, the majority of patients with 27 NPC are compound heterozygotes that often carry at least one private mutation, 28 presenting a challenge for the characterization and classification of individual variants. Niemann-Pick disease type C is a rare autosomal recessive lysosomal storage disorder 43 affecting 1 in 90,000 individuals (Vanier 2010; Wassif et al. 2016 ). In 95% of cases, 44 NPC is caused by mutations in the gene NPC1, which is required for the proper 45 transport of sterols from the lysosome to other subcellular compartments (Vanier 2010) . 46
While NPC is a clinically heterogeneous disorder with symptoms ranging from 47 hepatosplenomegaly to ataxia and seizures, the disease is defined by fatally 48 progressive neurodegeneration (Patterson et al. 2013; Vanier 2010) . These symptoms 49 are caused by the intracellular accumulation of cholesterol and glycolipids within late 50 endosomes and lysosomes (Wojtanik and Liscum 2003; Ory 2000) . This accumulation 51 is easily visualized in patient-derived fibroblasts using a fluorescent dye called filipin 52 which is used as a primary assay in the diagnosis of Niemann-Pick disease type C 53
(McKay Bounford and Gissen 2014). 54
More than 200 disease-causing mutations have been identified in NPC1 which 55 define a heterogeneous mutational spectrum that includes missense and nonsense 56 mutations, small duplication, deletion and insertion mutations, and splice-site mutations 57 The advent of CRISPR-Cas9-based genome editing has allowed for 71 modifications to genomes with a precision and efficiency unparalleled by previous 72 technologies (Mali, Esvelt, and Church 2013) . In brief, CRISPR-Cas9-based genome 73 editing relies on a guide RNA programmable bacterial endonuclease, Cas9, to induce a 74 targeted DNA double-stranded break (DSB). In the absence of a repair template, this 75 break is predominantly repaired by non-homologous end joining (NHEJ) which is 76 stochastic and leads to small insertions or deletions (Cho et al. 2013; Jinek et al. 2012; 77 Mali et al. 2013 ). Typically, even when a repair template is exogenously supplied, NHEJ 78 is responsible for the majority of genome editing outcomes with CRISPR-Cas9, making 79 the establishment of models with specifically designed modifications inefficient. 80
Recently, this challenge has been addressed with the introduction of CRISPR-Cas9-81 mediated base editing, which utilizes a nucleobase deaminase enzyme fused to a 82 catalytically impaired Cas9 enzyme capable of inducing only single-stranded breaks 83 (Rees and Liu 2018). These nucleobase deaminase enzymes, APOBEC1 and TadA for 84 cytosine and adenine base editing, respectively, operate on single-stranded DNA 85 (ssDNA), exclusively (Gaudelli et al. 2017; Komor et al. 2016 ). Similar to traditional 86 CRISPR-Cas9-based genome editing, this fusion protein can be targeted to a guide 87 RNA specified genomic locus. When the guide RNA binds to its target sequence, the 88 complementary strand is displaced, becoming available for modification by the 89 deaminase enzyme (Nishimasu et al. 2014 ). In practice, only a portion of the displaced 90 "R loop" is prone to deamination with the current generation of CRISPR-Cas9 base 91 editors, corresponding to an approximately 5 base pair editing window located 13-17 92 base pairs upstream from the protospacer-adjacent motif sequence (PAM) (Gaudelli et inosine which has base pairing preferences equivalent to guanosine (Yasui et al. 2008) . 96
The single-stranded nick produced on the unedited strand by the Cas9 enzyme then 97 induces endogenous DNA repair pathways that will utilize the edited strand as a 98
template, effectuating either a C•G to T•A or an A•T to G•C base pair transition. 99
Here, we demonstrate that by CRISPR-Cas9-mediated NPC1 gene editing, the 100 HAP1 cell line, a human near-haploid cell line, can serve as an effective model of 101
Niemann-Pick disease type C. By CRISPR-Cas9-based gene disruption, we show that 102 NPC1-deficient HAP1 cells exhibit the biochemical hallmarks of the disease. 103
Furthermore, we demonstrate that CRISPR-Cas9-mediated base editing allows for the 104 rapid and efficient generation of haploid models of unique NPC1 variants. These models 105 allow for the interrogation of individual variants in isolation, which was previously 106 infeasible for the vast majority of documented variants. Additionally, we demonstrate the 107 utility of our haploid models of NPC1 variants in clinical variant interpretation. 108
109
Results 110
Generation and characterization of an NPC1-deficient near-haploid cell line 112 113
As NPC is an autosomal recessive disorder, cellular disease modelling requires the 114 disruption of each allele present in the target cell type. This presents a challenge given 115 the diploid or often aneuploid nature of typical human cell lines, especially if uniform 116 allele disruption is desired. HAP1 cells, however, are a near-haploid human cell line 117 containing a single copy of each chromosome, with the exception of a heterozygous 118 fragment of chromosome 15, making them an excellent system for loss-of-function 119 disease modelling (Carette et al. 2011 ). We used CRISPR-Cas9-mediated gene 120 targeting to generate NPC1-deficient HAP1 cells. To disrupt NPC1 expression, we 121 selected several single guide RNAs (sgRNAs) with minimal computationally predicted 122 off-target activity which target exon 21 of the NPC1 locus. These sgRNAs were cloned 123 into plasmids allowing co-expression with Streptococcus pyogenes Cas9 (SpCas9) and 124 tested for editing efficiency. The two most highly active sgRNAs were transfected 125 separately into wildtype HAP1 cells (Supplemental Table S1 , Fig. 1A ). Following 72 126 hours of antibiotic selection to enrich for successfully transfected cells, isogenic clones 127 were isolated by limited dilution and screened by Sanger sequencing for locus 128 disruption. Out of fifteen clones screened, six isogenic cell clones were identified with 129 unique mutations in the targeted locus and three clones were carried forward for further harboured an insertion of an adenine nucleotide at the predicted double-stranded break 135 site, resulting in a frameshift and the formation of a premature stop codon four amino 136 acids downstream from the insertion (Fig. 1C) . The third clone, [NG_012795.1 NPC1: 137 g.54899_54904del], contained an in-frame six base pair deletion ( Fig. 1D ). To assess 138 whether these mutations were sufficient to disrupt NPC1 expression, we performed a 139 western blot for NPC1 protein. Both clones with frameshift mutations exhibited a 140 complete absence of NPC1 protein, while the third clone showed residual protein 141 expression and appeared to run as a doublet, with a second band at a slightly lower 142 molecular weight ( Fig. 1E ). For the first two clones, this indicates that both frameshift 143 mutations are sufficient in generating null NPC1 alleles. In the third clone, the doublet 144 staining of NPC1 likely indicates a heterogeneously glycosylated protein product, a 145 phenomenon which has been previously reported for a variety of NPC variants (Watari individually screened by Sanger sequencing by analyzing the genomic sequence 189 ranging from at least 100bp both up-and downstream of the sgRNA binding site, 190 between 8%-60% of isogenic clones were positively edited (Table 1) . Our system for 191 model generation resulted in clonal isolation in just over two weeks ( Fig. 2A ). The 192 editing in all but two of the nineteen variants isolated was contained to a single codon. 193
During the generation of the NPC1 p.R1077X variant, the editing window contained a 194 shorter than the wildtype amplicon (Fig. 2C) . By Sanger sequencing, we confirmed that 235 the shorter amplicon was indeed the result of exon 23 (114bp in length) exclusion ( Fig.  236   2C) . 237
Next, by analyzing NPC1 protein expression via western blot, we found that 238 mutant NPC1 expression varied in apparent molecular weight and level of expression. 239
Six of the nineteen variants -NPC1 p.R4H, NPC1 p.F402P, NPC1 p.Y634=, NPC1 p. 240
I635T, NPC1 p.V1158=, and NPC1 p.M1159T -ran with an equivalent molecular weight 241 to wildtype NPC1 protein (Fig. 3) . Each of these variants had similar NPC1 expression 242 compared to wildtype, with exception of NPC1 p.F402P, which had a moderate 243 reduction in protein expression. Seven of the nineteen variants -NPC1 p.E406G, NPC1 244 p.Y634C, NPC1 p.G765K, NPC1 p. L1060P, NPC1 p.I1061T, NPC1 p.D1097N, and 245 NPC1 c.3591+2T>C -ran as a single band at a lower molecular weight than wildtype 246 NPC1 protein ( Fig. 3) and exhibited reduced expression compared to wildtype. Of note, 247 the reduction in protein expression found in the NPC1 c.3591+2T>C implies that despite 248 the exon 23 exclusion leaving the open-reading-frame intact, the protein is likely being 249 targeted for degradation. Four of the nineteen variants -NPC1 p.F402S, NPC1 250 p.L785S, NPC1 p.D898N and NPC1 p.D945N -exhibited a reduction in total protein 251 and ran as two bands, one equivalent to wildtype and the other equivalent to that found 252 in the lower molecular weight mutants (Fig. 3) . The distinct molecular weights found in a 253 subset of the mutant variants modelled is consistent with findings in patient-derived 254 fibroblasts and have been attributed to endoplasmic-reticulum-associated protein 255 exhibited a complete absence of NPC1 protein (Fig. 3) . In preliminary assays, the NPC1 259 p.Y1267C model also displayed a total absence of NPC1 protein (Fig. 3) . The amino 260 acid change for this variant, however, occurs within immunogen sequence of the 261 primary C-terminal antibody. Upon further analysis with an N-terminal antibody, we 262 found that NPC1 p.Y1267C protein ran similarly to wildtype (Supplemental Fig. S4) . 263
Having observed different levels of expression and migration patterns in our models, we 264 assayed cholesterol homeostasis in each of the cell lines ( Fig. 4 fibroblasts, however, remains challenging as they are rarely found in isolation. 315
Here, we have developed a platform that allows for the rapid generation and 316 analysis of NPC1 variants. Specifically, our approach allows for the isolation and 317 expansion of mutant cell clones in less than 14 days. Using CRISPR-Cas9-mediated 318 base editing, we modelled nineteen unique NPC1 variants, demonstrating the utility of that these off-target events were independent of sgRNA sequence and were enriched in 331 highly transcribed regions. Accordingly, we carried out an analysis on three independent 332 cell clones for each variant of interest, minimizing the potential that any observed 333 phenotype to be off-target dependent. Furthermore, we performed RNA-sequencing on 334 the parental HAP1 line and nine edited cell clones representing the three biological 335 replicates from three of our modelled variants, NPC1 p.R1077X, NPC1 p.D1097N and 336 NPC1 c.3591+2T>C. Using these sequencing reads, we performed variant analysis 337 evaluating the distribution of mutations throughout the cell clones. While we found 338 between 9 to 20 mutations in each clone that were not present in the parental cell line, 339 no single mutation was shared by multiple cell clones indicating that the observed 340 cholesterol accumulation phenotype is independent of potential off-target base editing in 341 the transcriptome (Supplemental Fig. S6A ). Furthermore, of the mutations found there 342 was no apparent bias towards C to T or G to A substitutions in clones generated using 343 cytosine base editing and no apparent bias towards A to G or T to C substitutions in 344 clones generated using adenine base editing (Supplemental Fig. S6B ). This indicates 345 the mutations observed are unlikely true off-targets, but likely a result of random 346 mutation events. 347
The American College of Medical Genetics guidelines classify the results of 348 functional assays as strong evidence for or against variant pathogenicity (Richards et al. 349 2015) . We have shown that NPC1 perturbation leads to a readily visualized defect in 350 cholesterol trafficking in HAP1 cells. This makes haploid models of NPC1 variants an nucleotide substitutions. In the present study, we demonstrated efficient targeting using 361 multiple engineered SpCas9 variants (Table 1) Fig. S3 ). While these events were in the minority, they suggest the 382 boundaries of the SpCas9 base editing window are not absolute. Accordingly, it may be 383 possible to design enzymes with a shifted editing window, further expanding the catalog 384 of targetable mutations. 385
In this study, using CRISPR-Cas9-mediated gene editing, we have generated 386 and characterized three models of NPC1-deficiency, which represent the first human 387 haploid cell models of NPC. We demonstrated that these models effectively capture the 388 principle diagnostic readout of NPC. The sheer number of NPC1 variants, combined 389 with most patients being compound heterozygotes, presents a challenge to 390 understanding the disease mechanisms underlying individual patient variants. To 391 overcome this challenge, we sought to model unique NPC1 variants in HAP1 cells. We 392 demonstrated that this is readily achievable using CRISPR-Cas9-mediated base editing. 393
Finally, we showed that our haploid models of NPC1 variants allow for efficient variant 394 characterization and clinical interpretation. While we have focused on NPC, it is worth of 395 note that the largest class of known pathogenic mutations in humans are point 396 mutations (Landrum et al. 2016; Landrum et al. 2014) . Given the ease and efficiency of 397 our approach, one can envision applying this strategy to a wide variety of genetic 398 disorders, thus providing a platform for the establishment of detailed genotype-399 phenotype relationships across these many disorders. to-one solution of RIPA homogenizing buffer (50 mM Tris HCl pH 7.4, 150 nM NaCl, 1-454 mM EDTA) and RIPA double-detergent buffer (2% deoxycholate, 2% NP40, 2% Triton 455 X-100 in RIPA homogenizing buffer) supplemented with a protease-inhibitor cocktail 456 (Roche). Cells were subsequently incubated on ice for 30 minutes. Cells were then 457 centrifuged at 12000G for 15 minutes at 4°C and the supernatant was collected and 458 stored at -80°C. Whole protein concentration was measured using Pierce BCA Protein 459
Assay Kit according to the manufacturer's protocol (Thermo Fisher Scientific). SDS-460
Page separation was completed by running 2 μg of total protein on a NuPAGE™ 3-8% 461
Tris-Acetate gel (Thermo Fisher Scientific). Next, proteins were transferred to a 462 nitrocellulose membrane using the iBlot 2 transfer apparatus (Thermo Fisher Scientific). 463
A 5% milk solution in 1X TBST was used for blocking for 1 hour at room temperature. 464
The membrane was then incubated with the NPC1 primary antibody (Abcam: ab106534 465 in main body figures or Novus Biologicals H00004864-M02 in Supplemental Fig. S4) TRIzol™ Reagent (Thermo Fisher Scientific). Isolation of mRNA was isolated following 490 the manufacturer's protocol. Next, 500μg of mRNA was reverse transcribed using 491 SuperScript™ III Reverse Transcriptase (Thermo Fisher Scientific) following the 492 manufacturer's protocol. Quantitative PCR utilizing Fast SYBR green Master Mix 493 (Qiagen) on a Step One Plus Real Time PCR (Applied Biosystems) was performed. 494 NPC1 expression was analyzed by amplification using a forward primer spanning the 495 junction of exon 12 and 13, and a reverse primer specific to exon 13. Primers against 496 endogenous GAPDH were used as an internal control. ΔΔCt was analyzed to assess 497 fold changes between edited and unedited samples. All graphs were plotted as the mean with error bars indicating standard error. 519
Differences between groups was assessed by two-tailed Student's t-test. P-values less 520 than 0.05 were considered statistically significant. 521 522 Data Access 523 524 All sgRNA and primer sequences are available in Supplemental Table S2 . RNA-525 sequencing reads have been submitted to the Sequence Read Archive. 526 527 Acknowledgments 528
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